Table 5 Classes of other prescribed or used drugs reported by a subset of study participants who reported self-medication with cannabis in an online survey in Quebec from November 2020 to January 2021 (n = 247)
Likely indication | Drug class | Users (n = 247, 50.51%) |
|---|---|---|
Pain | Unspecified analgesic | 36 (14.57) |
Opioids | 20 (8.10) | |
NSAID | 46 (18.62) | |
Coanalgesic | 17 (6.88) | |
Muscle relaxant | 21 (8.50) | |
Anti-migraine | 5 (2.02) | |
Corticosteroid | 2 (0.81) | |
Intestinal anti-inflammatory drug (e.g., mesalamine) | 2 (0.81) | |
Mood/anxiety/sleep disorder | Antidepressant | 84 (34.01) |
Serotonin-norepinephrine reuptake inhibitor | 4 (1.62) | |
Anxiolytic | 30 (12.15) | |
Hypnotic (z-class or benzodiazepine) | 34 (13.77) | |
Antipsychotic | 27 (10.93) | |
Mood stabilizers | 4 (1.62) | |
Attention deficit hyperactivity disorder | Psychostimulant | 27 (10.93) |
Cardio-vascular/metabolic/digestive | Antidiabetic | 2 (0.81) |
Antiacid | 10 (4.05) | |
Antihypertensive | 5 (2.02) | |
Anticoagulant | 1 (0.40) | |
Beta-blocker | 5 (2.02) | |
Asthma/smoking/allergies | Antihistaminic | 2 (0.81) |
Nicotine replacement therapy | 1 (0.40) | |
Inhaled corticosteroid | 2 (0.81) | |
Others | Oral contraceptive | 2 (0.81) |
Chemotherapy | 1 (0.40) | |
Natural health product | 9 (3.64) | |
Others | 16 (6.48) |